• Catalyst Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Corporate Update

    Source: Nasdaq GlobeNewswire / 09 Aug 2021 16:39:16   America/New_York

    -Q2 2021 Total Net Revenues of $36.4 Million Reflect Strong Quarter over Quarter Growth

    -Q2 2021 GAAP Net Income of $12.2 Million; Non-GAAP Net Income of $17.4 Million

    -$155.3 Million in Cash and Investments and no Funded Debt at End of Q2-2021

    -Catalyst to Host Quarterly Conference Call at 8:30 AM ET Tomorrow

    CORAL GABLES, Fla., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

    “I am very pleased that our operational plan for 2021 and year to date financial results continue to deliver as originally planned, despite not yet being back to pre-Covid conditions. I believe that this portends well for the balance of the year, as we anticipate that patient access to physician practices will continue to improve. This should lead to abbreviated diagnostic times for new Lambert-Eaton Myasthenic Syndrome (LEMS) patients, which will mean that these patients will have access to Firdapse® much sooner,” said Patrick J. McEnany, Chairman and Chief Executive Officer of Catalyst Pharmaceuticals. “Additionally, in line with our strategic objectives we have recently expanded our senior leadership team with highly regarded pharmaceutical executives to help us accelerate our business and portfolio development activities and continue the transformation of the company.”

    Q2-21 Financial Results

    • Total revenues in Q2 2021 were $36.4 million, a 23% increase from $29.6 million for Q2 2020.
    • Total Firdapse® product revenue, net in Q2 2021 was $33.6 million, a 14% increase from $29.6 million, net for Q2 2020.
    • Operating income in Q2 2021 was $15.8 million, up from $10.3 million in Q2 2020.
    • GAAP net income in Q2 2021 was $12.2 million, or $0.12 per basic and $0.11 per diluted share, compared with GAAP net income in Q2 2020 of $9.8 million, or $0.09 per basic and diluted share.
    • Research and development expenses were $4.5 million for Q2 2021 compared to $4.4 million for Q2 2020.
    • Selling, general and administrative expenses for Q2 2021 totaled $11.5 million compared to $10.8 million for Q2 2020.
    • During Q2 2021, repurchased 732,951 shares of the Company’s common stock for approximately $3.7 million.
    • Ended Q2 2021 with $155.3 million in cash and investments and no funded debt.

    Corporate Milestones

    • Announced exclusive license and supply agreement with DyDo Pharma for the development and commercialization of Firdapse® in Japan.
    • During July 2021, strengthened our senior leadership team with onboarding of Dr. Preethi Sundaram as Chief Product Development Officer, who will lead our product portfolio development and management.
    • Expanded our strategic focus to include acquiring or in-licensing innovative, technology platforms and earlier stage programs in all therapeutic categories with the exclusion of oncology.
    • Actively engaged in evaluation of potential acquisitions and partnerships of innovative products or companies.
    • Second Firdapse® patent issued, further strengthening our intellectual property portfolio.
    • Added Molly Harper, a seasoned pharmaceutical executive, to our board of directors.
    • Hired a new Vice President to lead investor relations. This executive will join us on August 16, 2021.

    Balance Sheet and Key Activities in 2021

    The Company plans to continue investing in the following key activities in 2021:

    • Expansion of U.S. commercialization of Firdapse®.
    • Continue support for our Firdapse® long-acting formulation and other development programs.
    • Expanding, prosecuting and protecting our portfolio of intellectual property.
    • Expansion of investments in research and development, including acquiring earlier stage rare disease opportunities and innovative technology.

    More detailed financial information and analysis can be found in the Company's Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission (SEC) on August 9, 2021.

    Non-GAAP Financial Measures

    Non-GAAP1 net income for Q2-21 was $17.4 million ($0.17 per basic and $0.16 per diluted share), which excludes from GAAP net income of $12.2 million (i) stock-based compensation expense of $1.5 million, (ii) depreciation of $31 thousand, and (iii) the provision for income taxes of $3.7 million. This compares to non-GAAP1 net income for Q2-20 of $12.2 million ($0.12 per basic and $0.11 per diluted share), which excludes from GAAP net income of $9.8 million (i) stock-based compensation expense of $1.8 million, (ii) depreciation of $29 thousand, and (iii) the provision for income taxes of $0.6 million. A tabular presentation of non-GAAP1 net income for the three months and six months ended June 30, 2021 and 2020 is included on page 5 of this press release.

    _________________________

    1 Statements made in this press release include non-GAAP financial measures. Such information is provided as additional information and not as an alternative to Catalyst's financial statements presented in accordance with U.S. generally accepted accounting principles (GAAP). These non-GAAP financial measures are intended to enhance an overall understanding of Catalyst's current financial performance. Catalyst believes that the non-GAAP financial measures presented in this press release provides investors and prospective investors with an alternative method for assessing Catalyst's operating results in a manner that Catalyst believes is focused on the performance of ongoing operations and provides a more consistent basis for comparison between periods. Non-GAAP financial measures should not be considered in isolation or as a substitute for comparable GAAP accounting. Further, non-GAAP measures of net income used by Catalyst may be different from and not directly comparable to, similarly titled measures used by other companies.

    The non-GAAP financial measures in this press release exclude from the calculation of net income (i) the expense associated with non-cash stock-based compensation, (ii) depreciation expense, and (iii) the provision for income taxes.  Non-GAAP income per share is calculated by dividing non-GAAP income by the weighted average common shares outstanding.

    Conference Call
    Catalyst management will host an investment-community conference call and webcast at 8:30 a.m. ET, tomorrow, Tuesday, August 10, 2021 to discuss the financial results and provide a corporate update. Investors who wish to participate in the conference call may do so by dialing (877) 407-8912 for domestic and Canadian callers or (201) 689-8059 for international callers. Those interested in listening to the conference call live via the internet may do so by visiting the Investors page of the company's website at www.catalystpharma.com and clicking on the webcast link on the Investors home page. A webcast replay will be available on the Catalyst website for 30 days following the call by visiting the Investor page of the company's website at www.catalystpharma.com. 

    About Catalyst Pharmaceuticals
    Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. Catalyst's New Drug Application for Firdapse® (amifampridine) Tablets 10 mg for the treatment of adults with LEMS was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and Firdapse® is commercially available in the United States as a treatment for adults with LEMS. Further, Canada’s national healthcare regulatory agency, Health Canada, approved the use of Firdapse® (amifampridine) for the treatment of adult patients in Canada with LEMS.

    Firdapse® is currently being evaluated in clinical trials for the treatment of MuSK-MG and has received Orphan Drug Designation from the FDA for myasthenia gravis.

    Forward-Looking Statements
    This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including (i) the continuing effect of the COVID-19 pandemic on Catalyst's net product revenues and net income, (ii) Catalyst’s ability to locate and acquire new product candidates through acquisition or in-licensing, (iii) Catalyst’s ability to successfully develop any new product candidates acquired or in-licensed, (iv) Catalyst’s ability to successfully develop Firdapse® for other indications and to successfully develop and commercialize a long acting formulation of Firdapse®, and (v) those factors described in Catalyst's Annual Report on Form 10-K for fiscal year 2020 and Catalyst's other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

     
    CATALYST PHARMACEUTICALS, INC.
     
    CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
     
    (in thousands, except share data)
     
      For the Three Months
    Ended June 30,    		 For the Six Months
    Ended June 30,
      2021 2020 2021 2020
    Product revenue, net $33,636 $29,605 $63,841 $58,741
    License and other revenue  2,729  --  2,729  --
    Total revenues  36,365  29,605  66,570  58,741
                 
    Operating costs and expenses:            
    Cost of sales  4,545  4,140  9,226  8,291
    Research and development  4,450  4,350  7,457  8,573
    Selling, general and administrative  11,532  10,833  24,248  20,896
    Total operating costs and expenses  20,527  19,323  40,931  37,760
    Operating income  15,838  10,282  25,639  20,981
    Other income, net  62  111  143  448
    Net income before income taxes  15,900  10,393  25,782  21,429
    Provision for income taxes  3,719  613  5,938  1,223
    Net income $12,181 $9,780 $19,844 $20,206
             
    Net income per share:        
    Basic $0.12 $0.09 $0.19 $0.20
    Diluted $0.11 $0.09 $0.18 $0.19
             
    Weighted average shares outstanding:        
    Basic  103,407,803  103,414,523  103,610,138  103,410,881
    Diluted  107,734,924  106,730,423  107,299,262  106,433,862


    CATALYST PHARMACEUTICALS, INC.
    RECONCILIATION OF NON-GAAP METRICS (unaudited)
     
    (in thousands, except share data)
        
     For the Three Months
    		 For the Six Months
     Ended June 30,
    		Ended June 30,
      2021  2020  2021  2020
    GAAP net income$ 12,181  $ 9,780  $ 19,844  $ 20,206 
    Non-GAAP adjustments:           
    Stock-based compensation expense 1,518  1,794  3,089  3,314
    Depreciation 31  29  128  43
    Income tax provision 3,719  613  5,938  1,223
    Non-GAAP net income$17,449 $12,216 $28,999 $24,786
                
    Non-GAAP net income per share:           
    Basic
    		$0.17 $0.12 $0.28 $0.24
    Diluted$0.16 $0.11 $0.27 $0.23
                
    Weighted average shares outstanding – basic 103,407,803  103,414,523  103,610,138  103,410,881
    Weighted average shares outstanding – diluted 107,734,924  106,730,423  107,299,262  106,433,862
                


    CATALYST PHARMACEUTICALS, INC.
    CONDENSED CONSOLIDATED BALANCE SHEETS
     
    (in thousands)
     
     June 30,
    2021    		 December 31,
    2020
     (unaudited)  
    ASSETS   
    Current Assets:   
    Cash and cash equivalents$135,295 $130,237
    Short-term investments 19,980  10,041
    Accounts receivable, net 6,292  5,987
    Inventory 7,097  4,651
    Prepaid expenses and other current assets 7,641  8,328
    Total current assets 176,305  159,244
    Operating lease right-of-use asset 3,201  --
    Property and equipment, net 914  130
    Deferred tax assets 28,701  32,971
    Deposits 9  9
    Total assets$209,130 $192,354
        
    LIABILITIES AND STOCKHOLDERS’ EQUITY   
    Current Liabilities:   
    Accounts payable$2,924 $4,256
    Accrued expenses and other liabilities 13,211  18,500
    Total current liabilities 16,135  22,756
    Operating lease liability, net of current portion 4,051  --
    Total liabilities 20,186  22,756
        
    Total stockholders’ equity 188,944  169,598
    Total liabilities and stockholders’ equity$209,130 $192,354

    Media Contact
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com

Company Contact
Patrick J. McEnany
Catalyst Pharmaceuticals
Chief Executive Officer
(305) 420-3200
pmcenany@catalystpharma.com

    Primary Logo

Share on,